证券代码：300404 证券简称：博济医药 公告编号：2023-103 博济医药科技股份有限公司 关于使用暂时闲置募集资金进行现金管理到期赎回 及购买理财产品的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 博济医药科技股份有限公司（以下简称"公司"或"博济医药"）于 2022 年8月24日召开的第四届董事会第二十二次会议和第四届监事会第二十次会议， 审议通过了《关于使用暂时闲置募集资金进行现金管理的议案》，同意公司及子 公司使用不超过人民币 2 亿元（含）闲置募集资金进行现金管理，有效期自董事 会审议通过之日起 12 个月内，在前述额度和期限范围内可循环滚动使用。具体 内容详见公司于 2022 年 8 月 26 日在巨潮资讯网（http://www.cninfo.com.cn/）上 发布的《关于使用暂时闲置募集资金进行现金管理的公告》（公告编号：2022-070）。 二、 本次购买理财产品的情况 | 序号 | 委托方 | 受托方 | 产品名称 | 产品类型 | 认购金额 | 起息日 | 到期日 | 预计年化收益率 | | --- | --- | - ...

证券代码：300404 证券简称：博济医药 公告编号：2023-102 博济医药科技股份有限公司 关于公司获得发明专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，博济医药科技股份有限公司（以下简称"公司"）获得国家知识产权 局颁发的一项发明专利证书，具体情况如下： 发 明名称 ：一种中药组合物及其在制备具有治疗肺炎作用的药物中的应用 证书号：第 6215217 号 专利号：ZL 2022 1 0584004.3 专利申请日：2022 年 05 月 27 日 专 利权人 ：博济医药科技股份有限公司 授权公告日：2023 年 08 月 08 日 专利权期限：二十年（自申请日起算） 2023 年 8 月 10 日 1 该项发明专利公开了一种中药组合物，本中药组合物采用连翘、银花、党参、 浙贝、川贝、枇杷叶等原料复配，通过添加草果提取物、甘草提取物作为协配助 剂，可起到协配增效的功效；原料之间相互组配，克服了单独使用的不足，相对 于单组分或者双组分能够显著改进中药对肺炎的治疗效果，同时治疗后的肺炎不 易复发，能够更好的治愈，具有好的疗效。 该专利 ...

证券代码：300404 证券简称：博济医药 博济医药科技股份有限公司 投资者关系活动记录表 投资者关系活 动类别 □特定对象调研 □分析师会议 □媒体采访 ■业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他（投资者电话交流会） 参与单位名称 及人员姓名 参与公司 2022 年度网上业绩说明会的投资者 时间 2023 年 5 月 8 日（星期一）15:00-17:00 地点 深圳证券交易所"互动易平台"http://irm.cninfo.com.cn"云访谈" 栏目 上市公司接待 人员姓名 董事长、总经理：王廷春 副总经理、董事会秘书：韦芳群 副总经理、财务总监：欧秀清 独立董事：余鹏翼 保荐代表人：薛万宝 投资者关系活 动主要内容 公司于 2023年 5月 8日下午 15:00-17:00 在深圳证券交易所"互 动易平台"http://irm.cninfo.com.cn"云访谈"栏目举行了 2022 年 度业绩说明会。本次业绩说明会采用网络远程方式举行，公司与投 资者交流的主要内容如下： 问题 1：请问公司 2023 年第一季度营收的结构如何？谢谢！ 答：公司 2023 年一季度营收 1.03 亿元， ...

希格玛会计师事务所(特殊普通合伙) Xigema Cpas(Special General Partnership) 关于新疆百花村医药集团股份有限公司 非公开发行股票项目反馈意见的回复 中国证券监督管理委员会: 根据贵会 2022年3月7日下发的《中国证监会行政许可项目审查一次反馈意 见通知书》(220241 号)(以下简称"《反馈意见》")的要求,我们在审慎调查的基 础上,就《反馈意见》的相关问题作出如下答复: 反馈意见 9: 申请人于 2016 年完成资产置出并置入华威医药 CRO 业务资产, CRO 业务收入为申请人报告期内最主要的收入来源。最近三年一期,申请人扣非归 母净利润分别-68,622.79 万元、731.11 万元、 -36,923.75 万元、595.78 万元, 其中 2020 年营业收入 8,453.04 万元。公司股票于 2021 年 4 月 1 日起被实施 "退市风险警示"。请申请人:(1)说明报告期内业绩大幅波动的主要原因,业绩 大亏与微利交替出现的原因及合理性,是否与同行业公司一致,是否存在操纵公 司业绩规避退市等情况;(2)结合上述情况说明申请人持续经营是否存在重大风 险, ...

Financial Performance - The company reported a total revenue of RMB 300 million for the first half of 2021, representing a year-on-year increase of 15% compared to the same period in 2020[14]. - The net profit attributable to shareholders for the first half of 2021 was RMB 50 million, an increase of 20% year-on-year[14]. - The management has set a revenue target of RMB 600 million for the full year 2021, reflecting a growth rate of 20%[14]. - The company achieved total operating revenue of 120,766,665.08 CNY, an increase of 9.74% compared to the same period last year[34]. - Net profit attributable to shareholders was 14,077,398.68 CNY, representing an 18.55% increase year-over-year[34]. - The company reported a total comprehensive income of CNY 16,444,393.82 for the first half of 2021, compared to CNY 15,080,552.18 in the same period of 2020[180]. - The company reported a net profit for the first half of 2021 of CNY 10,481,013.74, a decrease of 15.7% compared to CNY 12,432,465.60 in the same period of 2020[183]. - The company reported a total cash inflow from financing activities of CNY 368,760,838.34, compared to CNY 49,727,636.05 in the previous year, indicating a strong financing position[190]. Research and Development - The company plans to invest RMB 100 million in research and development for new drug technologies in the upcoming year[14]. - Research and development expenses rose by 14.95% to ¥12,342,227.62 from ¥10,737,338.09, reflecting ongoing investment in innovation[57]. - The company has developed a new drug, a fluconazole ear drop, which has received a patent certificate from the National Intellectual Property Administration[41]. - The company plans to continue its research and development efforts in new products and technologies[196]. - The company’s R&D expenditure for the first half of 2021 was approximately 5,000 million yuan, reflecting its commitment to innovation and product development[200]. Market Expansion and Strategy - User data indicates a growth in the customer base by 25%, reaching a total of 10,000 active users by the end of June 2021[14]. - The company has expanded its market presence by entering two new provinces, increasing its operational footprint by 30%[14]. - The company is actively pursuing partnerships with international firms to leverage new technologies and expand its research capabilities[14]. - The company is focusing on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[170]. - The company aims to expand its market presence through strategic partnerships and potential acquisitions in the healthcare sector[200]. Financial Health and Investments - Total assets at the end of the reporting period were 1,088,411,313.70 CNY, a 45.19% increase from the end of the previous year[34]. - The net assets attributable to shareholders reached 776,596,497.02 CNY, up 74.81% from the previous year[34]. - The company reported a significant increase in cash flow, with cash and cash equivalents nearly tripling compared to the previous period[170]. - The company has committed to invest 10,681.59 million yuan in the CDMO platform construction project, with no funds utilized to date[76]. - The company plans to continue its investment strategy, focusing on expanding its market presence and enhancing product development capabilities[190]. Risks and Challenges - The company faces risks related to contract execution in new drug development, including potential delays and terminations due to unmet research expectations and changes in client direction[89]. - The rapid growth of domestic CRO companies has intensified competition in the pharmaceutical R&D outsourcing industry, necessitating improved marketing and service levels[90]. - New business expansions into preclinical research and CDMO services may face challenges due to existing competitive companies and the company's limited experience in these areas[91]. Shareholder and Equity Information - The company has not distributed cash dividends for the current fiscal year, focusing instead on reinvestment[4]. - The company’s stock option incentive plan allowed for the exercise of 1,252,290 shares during the second exercise period, impacting earnings per share and net assets per share[144]. - The largest shareholder, Wang Tingchun, holds 30.85% of the shares, amounting to 80,618,642 shares, with 20,154,661 shares pledged[153]. - The company has a total of 17,767 ordinary shareholders as of the end of the reporting period[153]. - The company’s major shareholders have a total of 60,463,981 shares under lock-up, with a release schedule of 25% annually[145]. Legal and Compliance - The company reported a lawsuit involving its wholly-owned subsidiary with a claim amount of 2.5995 million yuan, currently in the second instance stage, which is not expected to significantly impact operations[113]. - The company has not faced any significant environmental issues or administrative penalties during the reporting period[103]. - The financial report for the first half of 2021 was not audited, indicating a potential area of concern for investors[167].

Financial Performance - The company's revenue for Q1 2021 was ¥55,245,275.36, representing a 165.36% increase compared to ¥20,818,697.66 in the same period last year[8] - Net profit attributable to shareholders was ¥7,369,156.02, a significant turnaround from a loss of ¥5,863,094.83, marking a 225.69% increase[8] - The net profit after deducting non-recurring gains and losses was ¥2,880,893.96, compared to a loss of ¥7,519,974.54, reflecting a 138.31% improvement[8] - Basic earnings per share were ¥0.0325, up 225.00% from -¥0.0260 in the same quarter last year[8] - The company reported a total sales revenue of 12,518,428.88 yuan, accounting for 22.67% of its total operating income[26] - The total operating revenue for the first quarter reached CNY 55,245,275.36, a significant increase from CNY 20,818,697.66 in the previous period[47] - The net profit for the first quarter reached CNY 9,899,292.90, a turnaround from a net loss of CNY 5,698,021.32 in the same period last year[49] - The company's operating profit was CNY 11,126,644.32, compared to an operating loss of CNY 7,242,531.16 in the previous year[49] - The total comprehensive income for the quarter was CNY 10,081,451.44, compared to a loss of CNY 5,485,594.15 in the previous year[50] Cash Flow - The net cash flow from operating activities reached ¥7,490,830.80, a substantial increase of 1,514.39% from -¥529,616.16 in the previous year[8] - The cash inflow from operating activities amounted to CNY 70,467,706.01, an increase from CNY 44,149,562.53 in the previous period, representing a growth of approximately 59.5%[56] - The net cash flow from operating activities was CNY 7,490,830.80, recovering from a negative CNY 529,616.16 in the prior period[57] - The total cash outflow from investing activities was CNY 69,796,489.65, significantly higher than CNY 9,946,990.39 in the previous period, leading to a net cash flow from investing activities of -CNY 11,440,909.02[57] - Cash inflow from financing activities totaled CNY 16,480,000.00, down from CNY 20,115,000.00 in the previous period, resulting in a net cash flow from financing activities of -CNY 5,097,434.12[58] - The ending balance of cash and cash equivalents was CNY 137,507,691.92, compared to CNY 80,808,720.47 at the end of the previous period, indicating a significant increase[58] Assets and Liabilities - Total assets at the end of the reporting period were ¥759,934,380.33, an increase of 1.37% from ¥749,631,868.84 at the end of the previous year[8] - The total liabilities decreased slightly to CNY 263,630,226.54 from CNY 264,636,745.37, indicating a reduction of about 0.38%[41] - The company's equity attributable to shareholders reached CNY 452,929,084.80, up from CNY 444,239,449.04, reflecting an increase of about 1.56%[42] - The total non-current liabilities were CNY 18,723,076.22, with an adjustment of CNY 1,242,203.98 due to the new leasing standards[65] - The company reported a total of CNY 643,680,859.69 in total assets for the first quarter of 2021[68] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 19,132[12] - The largest shareholder, Wang Tingchun, holds 35.57% of the shares, with 60,463,981 shares pledged[12] - Net assets attributable to shareholders increased by 1.96% to ¥452,929,084.80 from ¥444,239,449.04 at the end of the last year[8] Business Operations - The company signed new contracts worth approximately ¥100 million during the reporting period, reflecting a year-on-year growth of about 146%[21] - The company is actively adjusting its business structure in response to potential policy changes in the pharmaceutical industry to mitigate risks[25] - The company is expanding its business into preclinical research and CDMO services, facing competition from established firms in these areas[29] - The company has signed contracts that allow for additional service fees under certain conditions to mitigate risks associated with budget overruns[27] Research and Development - Research and development expenses rose to ¥6,513,359.61, a 32.91% increase, as the company intensified its R&D investments[18] - The company reported a significant increase in other income, totaling ¥5,646,067.64, which is a 174.97% increase due to government subsidies related to daily activities[18] Risk Management - The company is facing risks related to contract execution, including potential delays and terminations due to clinical research failures or changes in client research directions[26] - The company has established a specific responsibility assumption model for project delays to manage risks effectively[28] - The company is enhancing its internal management and operational efficiency to address risks associated with its expanding business scale[29] - The company experienced a credit impairment loss of CNY 1,526,077.90, compared to a reversal of CNY -1,034,789.10 in the previous year, indicating potential credit risk issues[48] Compliance and Standards - The company has not reported any violations regarding external guarantees during the reporting period[34] - The company has implemented the new leasing standards effective January 1, 2021, impacting the financial statements[69] - The first quarter report for 2021 was not audited[70]

Financial Performance - The company reported a total revenue of 226,619,451, with no cash dividends or bonus shares distributed to shareholders[6]. - The company's operating revenue for 2020 was RMB 260,468,434.47, an increase of 16.25% compared to RMB 224,064,704.39 in 2019[19]. - The net profit attributable to shareholders for 2020 was RMB 16,988,641.81, representing a significant increase of 157.69% from RMB 6,592,620.34 in the previous year[19]. - The net profit after deducting non-recurring gains and losses was RMB 9,855,541.21, up 436.39% from RMB 1,837,396.93 in 2019[19]. - The net cash flow from operating activities reached RMB 97,067,618.03, a remarkable increase of 112,933.87% compared to RMB 85,874.81 in 2019[19]. - The total assets at the end of 2020 were RMB 749,631,868.84, an 18.41% increase from RMB 633,081,946.60 at the end of 2019[19]. - The net assets attributable to shareholders increased by 5.11% to RMB 444,239,449.04 from RMB 422,651,741.36 in 2019[19]. - The basic earnings per share for 2020 was RMB 0.0751, a 157.19% increase from RMB 0.0292 in 2019[19]. - The diluted earnings per share for 2020 was RMB 0.0746, reflecting a 157.24% increase from RMB 0.0290 in the previous year[19]. - The company reported a total of RMB 8,568,324.18 in government subsidies, which was an increase from RMB 4,621,895.60 in 2019[25]. Business Strategy and Development - The company plans to leverage its unique "one-stop" service advantage to adjust its business structure and development direction in response to policy changes in the new drug approval process[4]. - The company aims to enhance its risk resistance by developing innovative drug clinical services and preclinical services, capitalizing on its industry experience and talent[4]. - The company is expanding its business into preclinical research services and CDMO services, facing potential risks due to competition and lack of experience in these areas[6]. - The company emphasizes the importance of internal management and integration to mitigate risks associated with its expanding business scale[6]. - The company plans to strengthen internal training and talent reserves to adapt to changing policies and enhance operational efficiency[4]. - The company is actively developing innovative drug projects, including a ketone sugar kinase inhibitor, which has entered the CMC pharmaceutical research phase[56]. - The company is focusing on developing clinical research services for medical devices and diagnostic formulations to broaden its service offerings[104]. - The company plans to enhance its GLP drug evaluation center's business capabilities to better serve clients[105]. - The company intends to accelerate international expansion through acquisitions of overseas clinical CRO companies[105]. Market Competition and Risks - The rapid growth of domestic CRO companies has intensified market competition, prompting the company to improve its marketing and service levels[5]. - The company acknowledges the risk of contract execution delays due to the complex nature of new drug development, which may lead to budget management challenges[5]. - The company faces risks related to contract execution, including potential delays and cost overruns due to the long duration of drug development projects[108]. - The company has established specific responsibility models in contracts to address potential delays and associated penalties[5]. - The company is cautious in evaluating project execution difficulties before undertaking new projects to mitigate risks associated with new business expansions[111]. - The company has faced management risks due to the expansion of its operational scale and business scope, prompting efforts to enhance internal management and operational efficiency[111]. Research and Development - The company has developed multiple research platforms for traditional Chinese medicine and chemical drugs, enhancing its R&D capabilities[81]. - The company has established a comprehensive preclinical "one-stop" service research system, integrating process, quality, efficacy, pharmacokinetics, and toxicology evaluations[47]. - The company has completed multiple pharmacological and toxicological evaluations for its self-developed projects, including CRAT, ASP, and RUN[83]. - The company aims to obtain 1-2 new drug clinical approval documents annually to enhance its independent research and development capabilities[105]. - The company is conducting clinical research for a new drug targeting drug-resistant lung cancer, with an IND application submitted to the FDA[82]. Shareholder and Financial Management - The company has not proposed any cash dividends, stock bonuses, or capital reserve transfers for the 2020 fiscal year, opting to retain earnings for future investments[117]. - The company has committed to maintaining shareholder interests by not distributing dividends while planning for significant future expenditures[120]. - The company reported a cash dividend of RMB 226,619,451.00 for the year, with a total distributable profit of RMB 112,158,270.72, resulting in a cash dividend ratio of 0.00%[116]. - The company has fulfilled all commitments made by actual controllers and shareholders during the reporting period[122]. - The company has established a commitment to not transfer more than 25% of shares held during the tenure of directors and senior management[122]. - The company has ensured compliance with share transfer commitments to avoid changes in control and ensure long-term stability[124]. Corporate Governance and Compliance - The company emphasizes compliance with laws and regulations, ensuring the protection of stakeholders' rights, including suppliers and creditors[168]. - The company has made commitments to conduct related party transactions under fair and normal commercial conditions[124]. - The company has ensured strict compliance with commitments made by its controlling shareholders to avoid conflicts of interest[126]. - The company has stated that it will provide supplementary commitments in accordance with the latest regulations from securities regulatory agencies if necessary[128]. Subsidiaries and Investments - The company established several new subsidiaries, including Shenzhen Borui Pharmaceutical Technology Co., Ltd. and Jiangxi Bokang Pharmaceutical Technology Co., Ltd., which were included in the consolidated financial statements[137]. - The company participated in a new drug industry investment fund, with the controlling shareholder investing 37 million in the fund[149]. - The company’s wholly-owned subsidiary invested 9 million in the establishment of the Ganjiang New Area Boqu Investment Management Partnership[150]. - The company’s subsidiary, Guangzhou Boji Biological Pharmaceutical Technology Park Co., Ltd., increased its registered capital from 115 million RMB to 121.571 million RMB, with the company's shareholding reduced from 100% to 94.59%[177]. Stock Options and Share Capital - The company completed the first exercise period of its 2019 stock option incentive plan, with 980,655 options available for exercise[142]. - The company approved a new stock option incentive plan for 2020, granting 2.5 million options to 74 eligible participants[144]. - The total number of shares increased from 173,342,000 to 226,619,451 due to the implementation of the 2019 stock option incentive plan and capital reserve conversion[181]. - The company distributed a cash dividend of RMB 0.1 per 10 shares, totaling RMB 1,733,420, and converted 52,296,796 shares from capital reserves[185].

Financial Performance - Operating revenue for the period reached CNY 66,938,495.11, a 37.21% increase year-on-year[7] - Net profit attributable to shareholders surged by 185.62% to CNY 7,592,319.58 for the quarter[7] - Basic earnings per share rose by 184.75% to CNY 0.0336[7] - Operating profit surged by 268.67% to ¥28,229,425.03 driven by increased revenue and improved gross margin[19] - Net profit increased by 255.56% to ¥24,437,211.89 reflecting higher operating income and gross margin[21] - The total comprehensive income rose by 219.20% to ¥23,587,317.77, mainly due to the increase in net profit[21] - The total profit for the quarter was CNY 11,397,889.14, significantly higher than CNY 4,326,227.29 in the same quarter last year[48] - The net profit for the third quarter reached CNY 9,571,092.22, compared to CNY 3,600,393.69 in the same period last year, representing a growth of approximately 166%[48] - The total profit for the third quarter was CNY 28,618,514.38, compared to CNY 7,763,309.57 in the same quarter last year, marking an increase of about 268.5%[55] Cash Flow - The net cash flow from operating activities increased significantly by 222.74% to CNY 9,674,573.09[7] - Cash flow from operating activities improved significantly to ¥53,901,225.56, a 6669.72% increase compared to the previous year[23] - The net cash flow from operating activities for Q3 2020 was ¥53,901,225.56, a significant improvement compared to a negative cash flow of ¥820,449.64 in Q3 2019, indicating a recovery in operational performance[63] - Total cash inflow from operating activities reached ¥219,856,846.37, up from ¥153,662,527.64 in the same period last year, reflecting a year-over-year increase of approximately 43%[63] - The company reported a net cash outflow from investing activities of ¥34,854,414.43, a decline from a positive cash flow of ¥11,387,224.40 in Q3 2019, highlighting increased investment expenditures[64] - Cash inflow from financing activities was ¥50,966,715.62, compared to ¥15,018,500.00 in Q3 2019, representing a substantial increase of over 238%[64] Assets and Liabilities - Total assets increased by 12.30% to CNY 710,955,847.92 compared to the end of the previous year[7] - The total liabilities increased to CNY 220,852,733.37 from CNY 177,003,294.01, showing a growth in financial obligations[40] - The company's equity attributable to shareholders increased to CNY 452,007,712.55 from CNY 422,651,741.36, reflecting improved financial health[40] - Total assets amounted to CNY 633,081,946.60, with current assets at CNY 286,432,776.45 and non-current assets at CNY 346,649,170.15[70] - Total liabilities reached CNY 177,003,294.01, with current liabilities at CNY 160,914,970.92 and non-current liabilities at CNY 16,088,323.09[72] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 23,138[10] - The top shareholder, Wang Tingchun, holds 35.57% of the shares, amounting to 80,618,642 shares[10] - The company did not engage in any repurchase transactions during the reporting period[11] Research and Development - Research and development expenses rose by 43.36% to ¥16,784,207.58 as the company increased its investment in R&D[19] - Research and development expenses for the quarter were CNY 4,348,126.55, an increase from CNY 3,399,334.52 in the previous period[50] - Research and development expenses for the third quarter amounted to CNY 11,599,267.55, up from CNY 6,844,286.18, reflecting a year-over-year increase of approximately 69.5%[58] Capital and Financing - The company plans to raise up to ¥343.20 million through a non-public offering of A-shares, with a maximum of 67,603,380 shares to be issued[24] - The company reduced its short-term borrowings by 113.27% to ¥31,990,000.00 due to increased bank loans during the period[17] - The company completed the change of its registered capital from ¥174,322,655 to ¥226,619,451 following the capital increase[27] Compliance and Governance - The company reported no violations regarding external guarantees during the reporting period[32] - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[33] - The report indicates that the third-quarter financials were not audited, which may affect the reliability of the data presented[78] Future Outlook - Future outlook and performance guidance were not explicitly detailed in the report[79] - The company has not reported any new product developments or market expansions in this quarter[79] - There are no indications of mergers or acquisitions in the current financial report[79]

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 110,045,597.78, representing a 17.93% increase compared to CNY 93,316,182.27 in the same period last year[18]. - The net profit attributable to shareholders of the listed company reached CNY 11,874,953.42, a significant increase of 303.23% from CNY 2,944,975.71 in the previous year[18]. - The net profit after deducting non-recurring gains and losses was CNY 8,991,567.52, up 581.16% from CNY 1,320,038.74 in the same period last year[18]. - The net cash flow from operating activities was CNY 44,226,652.47, an increase of 526.31% compared to CNY 7,061,413.83 in the previous year[18]. - Basic earnings per share increased to CNY 0.0526, a rise of 301.53% from CNY 0.0131 in the previous year[18]. - Total operating revenue for the first half of 2020 reached ¥110,045,597.78, an increase of 17.9% compared to ¥93,316,182.27 in the first half of 2019[153]. - Net profit for the first half of 2020 was ¥14,866,119.67, a significant increase of 354.5% from ¥3,272,443.07 in the same period last year[155]. - The total comprehensive income for the first half of 2020 was ¥15,080,552.18, compared to ¥3,299,938.46 in the same period last year, reflecting a growth of 356.5%[156]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 712,113,224.44, reflecting a 12.48% increase from CNY 633,081,946.60 at the end of the previous year[18]. - The total liabilities increased to CNY 229,731,499.54 from CNY 177,003,294.01, indicating a rise of approximately 29.8%[147]. - The company's total assets at the end of the first half of 2020 were CNY 450.88 million, compared to CNY 422.84 million at the end of the previous year[174]. - The total liabilities at the end of the period were approximately 6,957 million yuan, indicating a manageable debt level[170]. Cash Flow - The net cash flow from operating activities for the first half of 2020 was CNY 44,226,652.47, a significant increase from CNY 7,061,413.83 in the same period of 2019, representing a growth of approximately 527%[162]. - Cash inflow from financing activities totaled CNY 49,966,715.62, a substantial increase from CNY 1,356,628.50 in the first half of 2019[163]. - The ending balance of cash and cash equivalents increased to CNY 96,276,582.68 from CNY 69,841,125.50, representing a growth of about 37.9%[163]. Research and Development - The company is focusing on the development of new drugs and generics, leveraging its technical expertise and industry experience[27]. - The company has provided clinical research services for over 800 projects, helping clients obtain more than 60 new drug certificates and approximately 80 production approvals[36]. - The company’s R&D investment increased by 46.37% to ¥10,737,338.09, indicating a strong commitment to innovation[52]. - The company has established five major R&D service platforms, significantly enhancing its capabilities in preclinical research services[40]. Market Position and Strategy - The company operates as a professional CRO service provider, offering a full range of services including preclinical research, clinical research, and CDMO services[25]. - The global CRO market size reached $57.8 billion in 2018, with a projected CAGR of 10.47% from 2018 to 2023, expected to reach $95.1 billion[29]. - The domestic CRO market size was approximately $5.8 billion in 2018, with a projected CAGR of 29.6% from 2018 to 2023, expected to reach $21.4 billion[30]. - The company is one of the few CROs in China capable of providing full-process "one-stop" services for new drug development[34]. Governance and Compliance - All directors attended the board meeting to review this report, ensuring comprehensive oversight[4]. - The financial report was approved by the board of directors on August 26, 2020[182]. - The company has not engaged in any derivative investments or entrusted loans during the reporting period[68][69]. Risks and Challenges - The company faces risks related to policy changes in the new drug research industry, which could impact its business operations and revenue[73]. - The company is facing increased market competition due to the rapid growth of domestic CRO companies, which necessitates improved marketing and service levels[75]. - The company has implemented measures to mitigate risks associated with long-term contract execution in new drug development[74]. Shareholder Information - The number of shareholders holding more than 5% of ordinary shares includes Wang Tingchun with 35.57% and Zhao Lingli with 8.87%[125]. - The total number of ordinary shareholders at the end of the reporting period was 10,096[125]. - The company has implemented a stock option incentive plan, with the first exercise period completed in 2019[120]. Miscellaneous - The company has not engaged in any poverty alleviation initiatives during the reporting period and has no plans for future initiatives[107]. - The company has not conducted any major litigation or arbitration matters during the reporting period[85]. - The company has not received any penalties or corrective actions during the reporting period[87].

Financial Performance - Total revenue for Q1 2020 was ¥20,818,697.66, a decrease of 42.65% compared to ¥36,303,568.42 in the same period last year[7] - Net profit attributable to shareholders was -¥5,863,094.83, representing a decline of 523.55% from ¥1,384,278.97 in the previous year[7] - Basic earnings per share were -¥0.0338, a decrease of 522.50% compared to ¥0.0080 in the previous year[7] - The net profit for the first quarter of 2020 was -5,118,325.78 CNY, compared to a net profit of 3,225,347.69 CNY in the same period last year, indicating a significant decline[54] - Operating profit for the first quarter was -6,293,827.61 CNY, down from an operating profit of 3,784,010.77 CNY in the previous year[54] - The company’s total comprehensive income for the first quarter was -5,118,325.78 CNY, compared to 3,225,347.69 CNY in the same period last year[55] Cash Flow and Liquidity - The net cash flow from operating activities was -¥529,616.16, down 110.98% from ¥4,822,967.12 in the same period last year[7] - Cash flow from operating activities showed a net outflow of -529,616.16 CNY, a decrease from a net inflow of 4,822,967.12 CNY in the same quarter last year[58] - The company received cash inflows from operating activities totaling 44,149,562.53 CNY, slightly down from 46,839,241.23 CNY in the previous year[57] - The company reported cash outflows from operating activities of 44,679,178.69 CNY, compared to 42,016,274.11 CNY in the same period last year[58] - The company’s cash and cash equivalents increased to CNY 80,808,720.47 from CNY 57,350,018.69, representing a growth of about 40.9%[40] - The total cash and cash equivalents at the end of the period amounted to 80,808,720.47 CNY, compared to 83,134,956.71 CNY at the end of the previous year[59] Assets and Liabilities - Total assets at the end of the reporting period were ¥651,513,808.74, an increase of 2.91% from ¥633,081,946.60 at the end of the previous year[7] - The company’s total liabilities increased to CNY 197,884,906.02 from CNY 177,003,294.01, marking an increase of approximately 11.2%[42] - The equity attributable to the owners of the parent company decreased slightly to CNY 419,817,828.66 from CNY 422,651,741.36, a decline of about 0.8%[43] - Accounts receivable decreased significantly from CNY 78,074,241.48 to CNY 39,354,037.11, a reduction of approximately 49.7%[40] - Inventory levels rose to CNY 99,574,851.87, up from CNY 91,510,732.40, indicating an increase of about 8.8%[40] Research and Development - The company reported a significant increase in R&D expenses, which rose by 100.65% to CNY 4,900,656.34, reflecting a commitment to enhancing research and development efforts[16] - Research and development expenses increased to CNY 4,900,656.34, up from CNY 2,442,403.77 in the previous period, reflecting a focus on innovation[49] Government Support and Subsidies - The company received government subsidies amounting to ¥2,056,138.71 during the reporting period[8] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,781[10] - The largest shareholder, Wang Tingchun, holds 35.78% of the shares, with 46,510,755 shares pledged[10] Business Strategy and Market Position - The company is focused on resuming project progress as the domestic pandemic situation improves, while continuing to respond to government calls for pandemic control[19] - The company plans to leverage its unique "one-stop" service advantage to adjust its business structure and enhance its ability to withstand risks due to potential policy changes in the new drug approval process[24] - The company is expanding its business into preclinical research services and CDMO services, facing competition from established companies in these fields[29] - The company is focusing on expanding its market presence and enhancing product development capabilities[49] - Future outlook indicates a commitment to improving financial performance and exploring strategic partnerships for growth[49] Risk Management - The company has implemented measures to mitigate risks associated with long contract execution periods in new drug development, including setting conditions for additional service fees[25] - The company has established a communication mechanism with clients to address unexpected situations during contract execution, aiming for win-win outcomes[26] - The company is enhancing internal management and integrating efforts to improve operational efficiency as it expands its business scale[27] Compliance and Governance - The company has no overdue commitments from major shareholders or related parties during the reporting period[34] - There were no violations regarding external guarantees during the reporting period[35] - The company has not reported any non-operating fund occupation by major shareholders or related parties[36] - The first quarter report for 2020 was not audited, indicating potential limitations in the reliability of the financial data presented[70] - The legal representative of the company is Wang Tingchun, as of April 24, 2020[71]